• McDonald's Q3 2026 Earnings Analysis
    Nov 4 2026
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're diving into the Golden Arches — McDonald's Q3 2026 earnings call. This one's got a little bit of everything: a U.S. turnaround story in progress, international strength, and some genuinely interesting strategic moves.

    **JORDAN:** Lots to unpack. There's value menu drama, beverage platform wins, hand-breaded chicken tests — even bone-in wings making a cautious comeback.

    **ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Okay, with that out of the way — let's talk numbers.

    **ALEX:** So McDonald's posted global comparable sales growth of 1.5% for Q3, with system sales up 4% in constant currency. Adjusted EPS came in at $3.57, which included a one-cent currency headwind — on a constant currency basis, that's EPS growth of 11% year-over-year. Stock actually popped over 6.6% on this report.

    **JORDAN:** Which tells you the market was bracing for worse, especially on the U.S. side. Let's break that down by segment, because the story really differs depending on where you look. U.S. comps were actually down 0.2% for the quarter — but here's the key detail: that masked a real improvement as the quarter progressed. July and August were negative, but September turned positive.

    **ALEX:** And that's not just noise — management specifically tied it to interventions they made mid-quarter. They restored digital offers like a $2 breakfast sandwich and free fries with a $1 purchase, shifted marketing dollars toward value platforms, and leaned harder into operational execution.

    **JORDAN:** The loyalty angle here is huge, by the way. CEO Chris Kempczinski made the point that McDonald's most frequent customers — who make up the majority of sales — are extremely sensitive to digital offers. When they pulled back some of those offers earlier in the year, it apparently hit baseline traffic hard. Putting them back worked almost immediately.

    **ALEX:** Meanwhile, international was the steadier story. International Operated Markets, think Australia, Germany, the U.K., grew comps 1.4%, even with real softness in France and disruption in Ukraine from the war escalation. Strip those two out and IOM actually beats expectations.

    **JORDAN:** And then the International Developmental Licensed Markets — that's the franchise-heavy, licensed structure — grew 4.2%, with Japan leading the way. Forty-four consecutive quarters of comp growth in Japan. That's wild consistency.

    **ALEX:** China was the drag there, given the tough macro environment, though management noted operational efficiency improved profitability even with soft sales.

    **JORDAN:** Let's talk strategy, because this is where it gets interesting for the long-term thesis. McDonald's is leaning hard into what they're calling "McDonald's > NEXT" — basically a multiyear overhaul touching menu, restaurant design, and technology.

    **ALEX:** The headline piece for U.S. investors right now is the value test. McDonald's just launched an eight-week test of two new entry-level value constructs — mix-and-match bundles and fixed bundles — across about 1,900 restaurants. And get this: separately, franchisees covering roughly 4,000 more restaurants didn't even wait for test results — they just started rolling out similar offers on their own.

    **JORDAN:** That's over 40% of the entire U.S. system already moving on this. That's a pretty strong signal of franchisee alignment, which matters a lot given McDonald's heavily-franchised model. They're targeting a national rollout in e

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
  • Colgate-Palmolive Q3 2026 Earnings Analysis
    Oct 30 2026
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're digging into Colgate-Palmolive's third quarter 2026 results, reported on October 30th.

    **ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Alright, with that out of the way—Alex, this was actually a pretty strong quarter for a company that's been dealing with a lot of noise.

    **ALEX:** Yeah, let's start with the big picture. Colgate posted organic sales growth across four of its five divisions and all four product categories—oral care, personal care, home care, and pet nutrition. That's broad-based, which matters because it means they're not leaning on just one hot business line.

    **JORDAN:** And the margin story is honestly the headline here. They faced a 300 basis point headwind from material inflation—that's resins, petrochemicals, pulp and paper, all elevated—but their productivity programs, "funding-the-growth" and this newer "Strategic Growth and Productivity Program," offset nearly all of it. CFO Stan Sutula said funding-the-growth alone delivered over 290 basis points of offset.

    **ALEX:** So basically a near-perfect hedge against inflation through internal efficiency rather than just jacking up prices.

    **JORDAN:** Right, and pricing still played a role too—80 basis points of favorable pricing, plus 20 basis points from mix. They've taken pricing every quarter this year: 220 basis points in Q1, 160 in Q2, 200 in Q3. They're clearly trying to stay ahead of the cost curve rather than react to it.

    **ALEX:** Free cash flow was up 7% year-to-date, and they've returned $2.2 billion to shareholders so far this year. That's a healthy capital return story even with all this cost volatility swirling around.

    **JORDAN:** Let's talk geography, because that's really where the story gets interesting. Emerging markets grew mid-single digits, led by India, Brazil, and China.

    **ALEX:** India was a standout—double-digit growth again, driven by premium innovation. China's trickier—the category itself is soft, lots of brick-and-mortar weakness, but Colgate's own China business grew high single digits by leaning hard into e-commerce and social platforms like Douyin.

    **JORDAN:** And Hill's Pet Nutrition—wow. Organic sales up 6.5% ex-private label. Prescription Diet cat was up double digits, dog up mid-single digits. The therapeutic side is really firing, and it's creating a halo effect on the wellness side of that business.

    **ALEX:** They also teased their "Fresh" line—the fresh pet food push with chicken and brown rice, beef and carrot, lamb and pumpkin diets. CEO Noel Wallace was clear they're rolling that out slowly and deliberately, protecting the Hill's brand reputation with vets rather than rushing for a quick win.

    **JORDAN:** Now, let's get to the part analysts clearly wanted more color on: the U.S. turnaround. This was a recurring theme in the Q&A.

    **ALEX:** Right, multiple analysts—Filippo Falorni, Andrea Teixeira—pushed on North America. Wallace acknowledged some green shoots in toothpaste market share, but was candid that this is a multi-quarter rebuild, not a quick fix.

    **JORDAN:** The structural piece was fascinating to me. Colgate is literally restructuring their North American go-to-market model—moving away from a traditional channel-based structure toward one built around digital, social, and what Wallace called "agentic commerce" connections. His quote was something like: the business was built for "a world of channels," but we're now in "a world that runs on connections."

    **ALEX:*

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
  • Altria Q3 2026 Earnings Analysis
    Oct 29 2026
    More earnings analysis: https://betafinch.com
    Groups: INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Altria's third quarter 2026 results, and there's a lot on the table — from a lawsuit against the FDA to a brand-new flavor lineup for nicotine pouches. I'm Alex, here with Jordan, and we're going to break it all down for you.

    **JORDAN:** Before we get into it — quick reminder, Alex, you know the drill.

    **ALEX:** Right, right. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Perfect. Okay, let's get into Altria's numbers.

    **ALEX:** So headline first: adjusted diluted EPS grew 4.8% in Q3, and 5.1% through the first nine months of the year. That's solid growth for a company that's often thought of as slow and steady.

    **JORDAN:** And here's the thing that jumped out at me — they actually raised guidance. Full-year adjusted EPS is now expected between $5.66 and $5.74, which works out to 4.5% to 6% growth off last year's $5.42. That's up from their original range of 2.5% to 5%. So management is feeling pretty confident here.

    **ALEX:** Yeah, and that confidence is coming largely from the smokeable products segment, which is still the earnings engine for Altria. Adjusted operating company income there grew 3.9% to $3.1 billion in the quarter. Margins expanded too, up to 64.5%.

    **JORDAN:** What's interesting is how they're doing it. This isn't just pure pricing power — it's a "total portfolio" strategy. Marlboro's holding the premium end, but they've also got Basic gaining share in the discount segment. Basic's retail share jumped 1.8 points year-over-year as more price-pressured smokers trade down.

    **ALEX:** And then there's the new kid — Marlboro Cowboy Cut. It's basically a lower-priced premium option designed to keep value-conscious Marlboro smokers in the franchise instead of losing them to discount brands entirely. It's already in about 100,000 stores, roughly 75% of cigarette volume nationally.

    **JORDAN:** Smart playbook, honestly. They've done this before with Marlboro Special Select and Marlboro Black — launch at an introductory price, then gradually take pricing up over time once it's established. And it seems to be working — Marlboro's share of the premium segment hit 60%, up slightly both year-over-year and sequentially.

    **ALEX:** Now let's talk about the smoke-free side of the business, because this is where things get really interesting strategically. On! nicotine pouches — shipment volume was up 13.3% in the quarter to 47.8 million cans.

    **JORDAN:** But retail share only ticked up 0.1 point year-over-year, and was actually down 0.3 sequentially. That tells you this category is getting fiercely competitive. Everybody's throwing flavors and higher nicotine strengths at the wall right now.

    **ALEX:** Which is exactly what Altria's subsidiary Helix is doing in response — they just rolled out on! PLUS 12-milligram nationally, and they're adding new flavors: Blueberry Mint and Mango Pineapple hit shelves this month, with Watermelon Mint coming in November.

    **JORDAN:** And don't sleep on the marketing push either — they hosted something called the "on!vitational," an invite-only golf tournament in Palm Beach. It's meant to be a recurring, multiyear brand platform. Altria's clearly trying to build lifestyle equity around on!, not just compete on nicotine strength and flavor.

    **ALEX:** Now, here's the part of this call I found most newsworthy — the regulatory fight. Altria's Helix and NJOY subsidiaries actually sued the FDA this quarter.

    **JORDAN:** Yeah, this is a big deal. The lawsuit is asking a court to force the FDA to stick to the 180-day review timeline that Congress set for product authorizatio

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
  • Coca-Cola Q3 2026 Earnings Analysis
    Oct 28 2026
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're cracking open Coca-Cola's third quarter 2026 results. KO had some really interesting numbers to unpack this quarter.

    **JORDAN:** Yeah, there's a lot here — strong volume, raised guidance, and some big structural changes brewing for next year. Should be a good one.

    **ALEX:** Before we dive in, just our standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Solid. Okay, let's get into it.

    **ALEX:** So headline numbers first. Coca-Cola posted 5% unit case volume growth and 7% organic revenue growth for Q3. That's genuinely strong, especially on top of a strong first half. Comparable EPS came in at $0.91, up 11% year-over-year, though two points of that was currency tailwind.

    **JORDAN:** And here's the thing that stood out to me — they actually RAISED full-year guidance. They're now expecting organic revenue growth of at least 5%, and comparable EPS growth of at least 11% versus the $3 base from 2025. Free cash flow guidance also moved up to at least $13 billion for the year.

    **ALEX:** Right, and the balance sheet is in great shape too — net debt leverage at 1.3 times EBITDA, which is actually below their target range of 2 to 2.5 times. CFO John Murphy used this word "optionality" a lot on the call, which I think is code for "we're sitting pretty and waiting to see what happens with that IRS case."

    **JORDAN:** That IRS dispute keeps popping up as kind of the elephant in the room. They're not giving specifics, but they're clearly positioning the balance sheet to handle whatever outcome comes down — best case or worst case.

    **ALEX:** Let's talk margins for a second, because that's where some real execution shows up. Comparable gross margin expanded about 170 basis points, operating margin up 110 basis points. And importantly — margin expansion didn't come at the cost of investment. They actually ramped up marketing spend, double-digit growth in above-the-line investment.

    **JORDAN:** That "more with more" philosophy Lauren Lieberman from Barclays asked about — basically, Coke's saying we can grow margins AND keep pouring money into brand building at the same time. That's not easy to pull off, so I think that's a genuine positive signal for the quality of this growth.

    **ALEX:** Now let's talk geography, because this is really a tale of different markets doing different things. North America was actually flat on volume — which sounds concerning at first —

    **JORDAN:** — but context matters here. That flatness was largely due to July 4th holiday timing shifting into Q2, plus they're cycling really strong prior-year comps on Topo Chico and BODYARMOR. Management pointed out volume actually improved sequentially each month through the quarter. And get this — Mr. Pibb posted another quarter of double-digit growth. Small brand, but a fun data point.

    **ALEX:** Meanwhile, emerging markets are carrying a lot of weight. Brazil was strong, India had all ten of its top brands growing double digits, and Africa delivered high single-digit volume growth despite tough comparisons. Mexico and Argentina remain challenging, but management says they're seeing encouraging progress.

    **JORDAN:** China's an interesting one — "subdued" consumer environment, cautious spending, soft domestic demand — but Coke still grew volume there, leaning hard into digital commerce and emerging channels to find growth even when the broader consumer isn't spending freely.

    **ALEX:** Let's talk about the Q&A, because there were some really pointed questions. Chris C

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
  • Procter & Gamble Q1 2027 Earnings Analysis
    Oct 22 2026
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Procter & Gamble's fiscal Q1 2027 results — reported October 22nd. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** And honestly, Alex, this is a fun one. P&G doesn't usually give us "volume up 2.4%, organic sales up 4%" headlines — that's the kind of growth they haven't posted together since like 2022.

    **ALEX:** Exactly. Let's set the scene. Organic sales grew 4.0% — and this is the first quarter they're reporting that number to one decimal place, by the way, a small disclosure change. Volume contributed 2.4 points of that growth, pricing added 0.4 points, and mix added over a point. The headline here is that this is volume-led growth, not price-led.

    **JORDAN:** Which matters a lot right now. In this consumer environment, growing because more people are buying your stuff — not just because you raised prices — that's the better kind of growth story.

    **ALEX:** All ten product categories grew. All six geographic regions grew. North America was up 3%, Europe up 4% with the UK leading at high-single-digits, and Greater China was the standout at 8% growth, driven by SK-II up 12% and Pampers up nearly 50%.

    **JORDAN:** That Pampers number in China is wild, but CFO Andre Schulten was upfront that it's partly benefiting from a competitor stumbling in that market. Take out that tailwind and China's still growing mid-single-digits organically, which on its own is a great result given how soft Chinese consumer sentiment has been.

    **ALEX:** Now let's talk bottom line. Core EPS came in at $2.00, up about 1% year-over-year, flat on a currency-neutral basis. Gross margin was actually down 150 basis points, operating margin down 80 basis points.

    **JORDAN:** And here's the tension in this quarter — productivity improved a strong 250 basis points, but that got eaten up by rising commodity costs, freight, and continued marketing investment. Schulten flagged that commodity headwinds are only going to get worse from here.

    **ALEX:** Right, let's talk about that number because it's a big one — $1.4 billion after-tax commodity cost headwind for the full fiscal year. That's tied to oil, assuming Brent crude around $100 a barrel. And when you add in currency headwinds, higher interest expense from recent M&A, and lower non-operating income, the total headwind below the operating line balloons to about $1.9 billion after tax, or $0.79 a share — that's 11% of last year's core EPS.

    **JORDAN:** And what's notable is they only felt about 5% of that commodity hit in Q1, with 8% guided for the full year. So Schulten was basically telling investors: brace for Q2, because that's when the bigger chunk of this flows through the income statement.

    **ALEX:** Speaking of guidance — despite all that cost pressure, P&G held its full-year guidance ranges. Organic sales growth of 1% to 3%, though they're clearly running ahead of that right now. Core EPS growth of 0% to 3%, landing between $6.89 and $7.11 a share. They did raise the all-in GAAP sales outlook, but that's just to reflect the Thorne acquisition, which closed in early October.

    **JORDAN:** Thorne is interesting — that's the wellness and supplements brand. Management was clear on the call that they want Thorne's existing team to keep leading the business, with P&G playing a supporting role on things like international expansion and supply chain, not a full-on integration.

    **ALEX:** They also reaffirmed free cash flow productivity guidance of 85-90%, and plan to re

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Philip Morris International Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Philip Morris International's third quarter 2026 results. This one's got a little bit of everything — record profits, a big strategic pivot in the U.S., and some real geopolitical headwinds.

    Before we jump in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Okay Alex, let's start with the headline numbers because they're honestly pretty strong. PMI posted organic net revenue growth of 7.1% in Q3, hitting $11.4 billion. Adjusted operating income crossed $5 billion for the first time ever, and margins hit almost 45%.

    **ALEX:** That's a big one. And EPS came in at $2.36, a new quarterly record, up about 6% excluding currency effects. So on the surface, this is a "records across the board" quarter.

    **JORDAN:** Right, but there's nuance. CFO Massimo Andolina was pretty transparent that full-year guidance is now trending toward the middle-to-lower half of their ranges — both for operating income growth and EPS growth. And it's not because the core business is struggling. It's really two things: geopolitical cost pressure from the Middle East and Ukraine conflicts, and a massive, intentional investment surge in the U.S.

    **ALEX:** Let's talk about the smoke-free story first, because that's really the heart of PMI's whole transformation. Smoke-free products now make up 40% of total revenue, and in over 30 markets, they're already more than half of revenue. IQOS, their heated tobacco brand, saw adjusted in-market sales growth accelerate to 7.1% — or over 10% if you strip out Japan and Poland, which both have unique headwinds right now.

    **JORDAN:** Japan's going through this bumpy excise tax transition — they raised taxes twice this year on heated tobacco specifically, which caused some pantry-loading distortions in the data. Poland's dealing with a flavor ban. But outside those two, the growth story is honestly remarkable — double-digit IMS growth in Italy, Greece, Spain, Germany, the Netherlands, UK. And get this — their international heated tobacco and cigarette combined market share crossed 30% for the first time ever.

    **ALEX:** And then there's VEEV, their e-vapor brand — shipments up 62% in the quarter, becoming the number one closed pod brand in Europe. That's a smaller piece of the pie but growing incredibly fast.

    **JORDAN:** Now let's get into the part everyone's really watching — the U.S. and ZYN. This is where it gets interesting, and honestly, a little messy in the near term.

    **ALEX:** So ZYN had a rough patch earlier this year with volume growth below the category rate. Management's answer was a two-pronged strategic overhaul. First, they're massively expanding the product lineup — new flavors, new nicotine strengths including ZYN Ultra at 9 and 11 milligrams — basically chasing consumers who'd drifted to competitors for higher-nicotine options.

    **JORDAN:** And it seems to be working — they said category offtake share increased about 1.4 points from June to September. But the second piece is the bigger deal: they're repositioning pricing by moving their flagship cans from 15 pouches to 20 pouches at the same price. Andolina called it a value proposition improvement for consumers, but mathematically, that's roughly a 25% cut in revenue per pouch.

    **ALEX:** That's a huge deal. And combined with the step-up in marketing spend — U.S. SG&A hit around $370 million in Q3 with another 10% sequential jump expected in Q4 — the company is basically telling investors: expect U.S. profitability to be near zero or even slightly negative next quarter.

    **

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
  • Abbott Laboratories Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

    **JORDAN:** And I'm Jordan. We've got a genuinely big one today — Abbott Laboratories dropped some major news alongside their Q3 numbers.

    **ALEX:** We'll get to that in a second, but first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** With that out of the way, Alex, let's start with the headline because it's not every day a 138-year-old company announces it's splitting itself in two.

    **ALEX:** Right — Abbott announced it's spinning off its entire nutrition business into a standalone, publicly traded company by the end of 2027. We're talking about Similac, PediaSure, Ensure, Glucerna, Pedialyte — the whole $8.5 billion nutrition empire, 16,000 employees, 14 manufacturing sites. CEO Robert Ford said this would actually be the largest pure-play healthy nutrition company in the world, and they expect it to qualify for S&P 500 inclusion on its own.

    **JORDAN:** And the CEO pick is interesting too — Daniel Salvadori, who's run their Established Pharma and Nutrition division, is taking the reins of the new company. Ford called his team "battle-tested," which, if you've followed Abbott's infant formula saga the last few years — recalls, litigation, supply shortages — that's not an exaggeration.

    **ALEX:** The strategic logic here is basically: nutrition used to be a healthcare-professional-driven category, now it's a consumer wellness category, and those two worlds need different playbooks, different investment cycles, different marketing muscle. Ford's view is both companies do better focused and independent rather than living under one roof.

    **JORDAN:** And for shareholders, it's structured as a tax-free spin — you'll own shares of both companies when it's done. Abbott's also planning to have the new nutrition company raise some debt, with proceeds flowing back to Abbott, and both companies will maintain investment-grade ratings.

    **ALEX:** What's the math on what's left behind? Because that's really the investor question here.

    **JORDAN:** Right, this is the key number. CFO Phil Boudreau said stripping nutrition out of the current portfolio, Abbott's remaining business — MedTech, Diagnostics, Established Pharma — would see sales growth accelerate by 50 to 100 basis points, gross margin expand by over 200 basis points, and operating margin up roughly 100 basis points. So the pitch is: a leaner, faster-growing, higher-margin Abbott emerges on the other side.

    **ALEX:** Now let's talk actual Q3 results, because they were solid. Sales grew 7%, EPS grew 9% — both numbers accelerating from the first half of the year. Adjusted EPS came in at $1.42, right in line with guidance and consensus.

    **JORDAN:** Breaking it down by segment — Diagnostics grew 6.5%, with Core Lab up 5.5% on strong demand across the U.S., Europe, Japan, and Latin America. But the real story there is Cancer Diagnostics, up 14%, largely thanks to the Exact Sciences integration — that's Cologuard. They also just launched their first blood-based colorectal cancer screening test in September, making Abbott the only company offering both stool-based and blood-based options.

    **ALEX:** Nutrition — even as it heads for the exit — actually had a good quarter. Sales up 5%, broad-based across all four categories. Pediatric nutrition was the standout at 9% growth, helped by those WIC contract wins that let Abbott reclaim market leadership.

    **JORDAN:** Medical Devices grew 8%, led by electrophysiology and rhythm management, both posting double-digit growth. The Volt PFA catheter is gaining serious traction after its

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • 3M Q3 2026 Earnings Analysis
    Oct 20 2026
    More earnings analysis: https://betafinch.com
    Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into 3M's third quarter 2026 results, reported October 20th. This is a loaded one, folks — strong numbers, a major Amazon partnership, and a lot of forward-looking commentary on 2027. Before we get into it, though, the standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: And honestly, Alex, there's a lot to unpack here. 3M stock jumped over 5% on this print, so let's figure out why.

    ALEX: Let's start with the headline numbers. Organic growth of 3.3% for the quarter, operating margin of 26.2% — up 110 basis points year-over-year — adjusted EPS of $2.50, up 12%, and free cash flow of $1.2 billion. They returned $600 million to shareholders, split between dividends and buybacks.

    JORDAN: And importantly, they raised full-year EPS guidance to $9.10-$9.15, up from the prior range. That's roughly 11-12% growth for the year. Management also reaffirmed they expect organic growth above 3.5% for 2026, with Q4 actually accelerating to over 4%.

    ALEX: That acceleration story is interesting because it's backed by real data — backlog was up high-teens year-over-year heading into Q4, and orders grew high single digits in the quarter. That's not just hopeful talk, that's visibility.

    JORDAN: Right, and CFO Anurag Maheshwari broke down where the margin expansion is coming from — gross margins were up 230 basis points, driven by procurement savings, better quality control, and higher factory utilization. They've closed 16 manufacturing sites this year already, with 10 more targeted over the next year. That footprint simplification is expected to keep paying off well beyond 2027.

    ALEX: Now let's get to the part everyone's been buzzing about — Expanded Beam Optical, or EBO. This is 3M's connector technology for AI data center infrastructure.

    JORDAN: This is the big one. They filed an 8-K the night before the call announcing they issued Amazon a warrant for up to 3.2 million shares — about 0.6% of 3M's stock — tied to Amazon hitting $6 billion in cumulative purchases of optical connectivity and data-center-related products over seven years, plus other milestones.

    ALEX: CEO Bill Brown was careful to frame this as strategic validation rather than a guaranteed revenue stream. He emphasized there's no firm volume commitment — 3M has to "earn the right" to that business. But symbolically, locking in a warrant structure with Amazon, on top of the previously announced Microsoft Azure partnership, signals real traction with hyperscalers.

    JORDAN: And they paired that with a manufacturing deal — a contract agreement with Genius Electronic Optical, or GSEO, plus taking a 4.7% equity stake in that company to secure supply chain capacity. 3M's doubling its internal ferrule manufacturing capacity, and GSEO can reportedly scale multiples beyond that.

    ALEX: Sizing it for listeners — EBO revenue this year is around $40 million. Management expects that to roughly double next year, maybe a bit more. They've pegged the total addressable market at around $2 billion by 2028. So it's small today, but the growth trajectory and the ecosystem-building — they mentioned a Multi-Source Agreement that's grown from 17 to 63 member companies — suggests this could become a meaningful growth vertical.

    JORDAN: Let's talk segments for a second, because the picture is mixed. Safety & Industrial had a standout quarter, up 7% organically, driven by commercial excellence and new product ramp. Transportation & Electronics was basically flat at 0.5%, dragged down by co

    This episode includes AI-generated content.
    Show More Show Less
    8 mins